3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pain
14
Multiple Myeloma
12
Pain, Postoperative
9
Neoplasms
9
Agnosia
8
Lymphoma, Non-Hodgkin
6
Lung Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Cancer Pain
5
Neoplasm Metastasis
4
Lymphoma
4
Leukemia
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Burkitt Lymphoma
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, B-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Hairy Cell
3
Hematologic Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Trigger Finger Disorder
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Interventions
Carboplatin
158
Paclitaxel
152
Bevacizumab
85
Gemcitabine
48
liposomal doxorubicin
47
Taxes
47
Topotecan
41
Cisplatin
34
pembrolizumab
33
Cyclophosphamide
27
olaparib
25
Immunoglobulin G
24
Disulfides
24
Specimen Handling
20
Docetaxel
20
Drug Therapy
19
Magnetic Resonance Spectroscopy
17
niraparib
16
Doxorubicin
16
Biopsy
15
mirvetuximab soravtansine
14
Hyperthermic Intraperitoneal Chemotherapy
13
rucaparib
12
Nivolumab
12
Cytoreduction Surgical Procedures
10
Albumin-Bound Paclitaxel
10
veliparib
9
Platinum
9
Chemotherapy, Adjuvant
9
130-nm albumin-bound paclitaxel
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Fallopian Tube Neoplasms
×
Acetaminophen
×
Clear all
NCT06824467
2026-05-08
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled